Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases:
"Research into the efficacy of medical marijuana is currently at different stages for different types of diseases. The most advanced studies in humans provide moderate-quality evidence for moderate effects that benefit patients with Parkinson Disease and Multiple Sclerosis. There is also low-qu...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Hershey, Pennsylvania (701 E. Chocolate Avenue, Hershey, Pennsylvania, 17033, USA)
IGI Global
2023.
|
| Schlagworte: | |
| Online-Zugang: | DE-863 |
| Zusammenfassung: | "Research into the efficacy of medical marijuana is currently at different stages for different types of diseases. The most advanced studies in humans provide moderate-quality evidence for moderate effects that benefit patients with Parkinson Disease and Multiple Sclerosis. There is also low-quality evidence for mild-to-moderate effects that benefit patients with Epilepsy and Huntington Disease. The best success in reducing spasticity, relieving pain, decreasing bladder overactivity, reducing anxiety and improving quality of sleep was achieved using a 50:50 mixture of Cannabidiol (CBD):delta-9-THC. Reducing frequency and duration of seizures in children with intractable epilepsy is achieved using CBD alone. Future studies can hopefully improve the quality of evidence by including control groups, recruiting more participants, and following them up for longer periods of time. In the meanwhile, the cellular and molecular mechanisms responsible for alleviating these neurological symptoms in animals and humans are being investigated. Some of the anti-inflammatory and neuroprotective effects are mediated through one or both of the cannabinoid receptors CB1 and CB2 distributed on immune and neural cells, while some of the anti-epileptic effects are mediated through other receptors found in the central nervous system. Animal studies show that cannabinoids are effective anti-inflammatory and anti-tumor agents. In experimental xenograft models for brain cancer, lung, breast, colorectal, pancreatic and other cancers, treatment with either CBD alone or in mixtures with THC, significantly shrinks the tumors, inhibits tumor cell migration, slows metastasis, disrupts tumor blood vessel formation (angiogenesis), inhibits tumor cell proliferation and increases tumor cell death. Future studies are warranted to investigate these anti-tumor effects in human cancer patients, however, a small study on a dozen brain cancer patients demonstrated a modest increase in overall survival, and a case study on a lung cancer patient who refused chemotherapy and used cannabinoids instead reported a remarkable regression of the lung cancer tumors. Research efforts are intensifying to elucidate the multitude of cell signaling mechanisms that might be involved in mediating these remarkable anti-cancer and anti-angiogenic effects. The implications are that the next decade will be the dawn of a new era of pharmacotherapeutic applications of medical marijuana treatments in oncology for all cancer types, neurology for all movement disorders, demyelinative and dementia-causing neurodegenerative diseases, rheumatology and gastroenterology for all autoimmune and inflammatory disorders, and palliative care medicine for anxiety and pain management. This publication will include 15 chapters by experts on the use of cannabinoids and medical marijuana in different types of cancer and different types of neurologic or inflammatory diseases. Some authors will discuss the physiologic and biochemical mechanisms while others will report on clinical benefits and pharmacological challenges"-- |
| Beschreibung: | 20 PDFs (406 Seiten) Also available in print. |
| Format: | Mode of access: World Wide Web. |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9781668456538 |
| Zugangseinschränkungen: | Restricted to subscribers or individual electronic text purchasers. |
Internformat
MARC
| LEADER | 00000nam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-98-IGB-00296569 | ||
| 003 | IGIG | ||
| 005 | 20230313190106.0 | ||
| 006 | m eo d | ||
| 007 | cr bn||||m|||a | ||
| 008 | 230310s2023 pau fob 001 0 eng d | ||
| 020 | |a 9781668456538 |q PDF | ||
| 020 | |z 1668456524 |q hardcover | ||
| 020 | |z 9781668456521 |q print | ||
| 024 | 7 | |a 10.4018/978-1-6684-5652-1 |2 doi | |
| 035 | |a (CaBNVSL)slc00004108 | ||
| 035 | |a (OCoLC)1348644527 | ||
| 040 | |a CaBNVSL |b eng |e rda |c CaBNVSL |d CaBNVSL | ||
| 050 | 4 | |a RM666.C266 |b M43 2023e | |
| 060 | 0 | 0 | |a WB 925 |b .M43 2023e |
| 082 | 7 | |a 615.3/23648 |2 23 | |
| 245 | 0 | 0 | |a Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases |c Rana R. Zeine and Brian W. Teasdale. |
| 264 | 1 | |a Hershey, Pennsylvania (701 E. Chocolate Avenue, Hershey, Pennsylvania, 17033, USA) |b IGI Global |c 2023. | |
| 300 | |a 20 PDFs (406 Seiten) | ||
| 336 | |a text |2 rdacontent | ||
| 337 | |a electronic |2 isbdmedia | ||
| 338 | |a online resource |2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Chapter 1. Medicinal cannabis for Alzheimer's disease -- Chapter 2. Protective effects of cannabis in neuroinflammation-mediated Alzheimer's disease -- Chapter 3. Cannabinoid efficacy for developmental epileptic encephalopathy (DEE) intractable seizure control: a systematic review of the literature -- Chapter 4. Medical cannabis in the treatment of epilepsy -- Chapter 5. Anti-tumor effects of cannabinoids in brain, lung, breast, prostate, colorectal, and pancreatic cancers: a systematic review of the literature -- Chapter 6. Cannabinoid neurobiology and medical cannabis intervention for amyotrophic lateral sclerosis (ALS): understanding the molecular mechanisms of action -- Chapter 7. Role of cannabinoids in the regulation of amyotrophic lateral sclerosis (ALS) -- Chapter 8. Neurobiology of cannabinoids and medical cannabis in therapeutic intervention for multiple sclerosis: understanding the molecular mechanisms of action -- Chapter 9. Pros and cons of cannabinoids as a potential therapeutic target for treating Parkinson's disease: cannabinoid receptor-mediated mechanism of action -- Chapter 10. The uses of cannabinoids in medicine and their spectroscopic applications -- Chapter 11. Therapeutic advantages of cannabimimetic plants: can they substitute medical cannabis? -- Chapter 12. History and legislative changes governing medical cannabis in Indonesia -- Chapter 13. A case study on the integration of cannabis law enforcement in new jersey. | |
| 506 | |a Restricted to subscribers or individual electronic text purchasers. | ||
| 520 | |a "Research into the efficacy of medical marijuana is currently at different stages for different types of diseases. The most advanced studies in humans provide moderate-quality evidence for moderate effects that benefit patients with Parkinson Disease and Multiple Sclerosis. There is also low-quality evidence for mild-to-moderate effects that benefit patients with Epilepsy and Huntington Disease. The best success in reducing spasticity, relieving pain, decreasing bladder overactivity, reducing anxiety and improving quality of sleep was achieved using a 50:50 mixture of Cannabidiol (CBD):delta-9-THC. Reducing frequency and duration of seizures in children with intractable epilepsy is achieved using CBD alone. Future studies can hopefully improve the quality of evidence by including control groups, recruiting more participants, and following them up for longer periods of time. In the meanwhile, the cellular and molecular mechanisms responsible for alleviating these neurological symptoms in animals and humans are being investigated. Some of the anti-inflammatory and neuroprotective effects are mediated through one or both of the cannabinoid receptors CB1 and CB2 distributed on immune and neural cells, while some of the anti-epileptic effects are mediated through other receptors found in the central nervous system. Animal studies show that cannabinoids are effective anti-inflammatory and anti-tumor agents. In experimental xenograft models for brain cancer, lung, breast, colorectal, pancreatic and other cancers, treatment with either CBD alone or in mixtures with THC, significantly shrinks the tumors, inhibits tumor cell migration, slows metastasis, disrupts tumor blood vessel formation (angiogenesis), inhibits tumor cell proliferation and increases tumor cell death. Future studies are warranted to investigate these anti-tumor effects in human cancer patients, however, a small study on a dozen brain cancer patients demonstrated a modest increase in overall survival, and a case study on a lung cancer patient who refused chemotherapy and used cannabinoids instead reported a remarkable regression of the lung cancer tumors. Research efforts are intensifying to elucidate the multitude of cell signaling mechanisms that might be involved in mediating these remarkable anti-cancer and anti-angiogenic effects. The implications are that the next decade will be the dawn of a new era of pharmacotherapeutic applications of medical marijuana treatments in oncology for all cancer types, neurology for all movement disorders, demyelinative and dementia-causing neurodegenerative diseases, rheumatology and gastroenterology for all autoimmune and inflammatory disorders, and palliative care medicine for anxiety and pain management. This publication will include 15 chapters by experts on the use of cannabinoids and medical marijuana in different types of cancer and different types of neurologic or inflammatory diseases. Some authors will discuss the physiologic and biochemical mechanisms while others will report on clinical benefits and pharmacological challenges"-- |c Provided by publisher. | ||
| 530 | |a Also available in print. | ||
| 538 | |a Mode of access: World Wide Web. | ||
| 588 | |a Description based on title screen (IGI Global, viewed 03/10/2023). | ||
| 650 | 0 | |a Marijuana |x Therapeutic use. | |
| 650 | 2 | |a Cannabinoids |x analysis. | |
| 650 | 2 | |a Medical Marijuana |x therapeutic use. | |
| 650 | 2 | |a Neurodegenerative Diseases |x drug therapy. | |
| 653 | |a Cancer. | ||
| 653 | |a Developmental Epileptic Encephalopathies (DEE) | ||
| 653 | |a Epilepsy. | ||
| 653 | |a Ethical Issues. | ||
| 653 | |a Medical Marijuana. | ||
| 653 | |a Multiple Sclerosis. | ||
| 653 | |a Neurobiology of Cannabinoids. | ||
| 653 | |a Neurodegenerative Diseases. | ||
| 653 | |a Parkinson's. | ||
| 653 | |a Spectroscopic Applications. | ||
| 653 | |a Therapeutic Intervention. | ||
| 700 | 1 | |a Teasdale, Brian |e editor. | |
| 700 | 1 | |a Zeine, Rana |d 1962- |e editor. | |
| 710 | 2 | |a IGI Global, |e publisher. | |
| 776 | 0 | 8 | |i Print version: |z 1668456524 |z 9781668456521 |
| 966 | 4 | 0 | |l DE-863 |p ZDB-98-IGB |q FWS_PDA_IGB |u http://services.igi-global.com/resolvedoi/resolve.aspx?doi=10.4018/978-1-6684-5652-1 |3 Volltext |
| 912 | |a ZDB-98-IGB | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-98-IGB-00296569 |
|---|---|
| _version_ | 1825936821718089728 |
| adam_text | |
| any_adam_object | |
| author2 | Teasdale, Brian Zeine, Rana 1962- |
| author2_role | edt edt |
| author2_variant | b t bt r z rz |
| author_facet | Teasdale, Brian Zeine, Rana 1962- |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM666 |
| callnumber-raw | RM666.C266 M43 2023e |
| callnumber-search | RM666.C266 M43 2023e |
| callnumber-sort | RM 3666 C266 M43 42023E |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-98-IGB |
| contents | Chapter 1. Medicinal cannabis for Alzheimer's disease -- Chapter 2. Protective effects of cannabis in neuroinflammation-mediated Alzheimer's disease -- Chapter 3. Cannabinoid efficacy for developmental epileptic encephalopathy (DEE) intractable seizure control: a systematic review of the literature -- Chapter 4. Medical cannabis in the treatment of epilepsy -- Chapter 5. Anti-tumor effects of cannabinoids in brain, lung, breast, prostate, colorectal, and pancreatic cancers: a systematic review of the literature -- Chapter 6. Cannabinoid neurobiology and medical cannabis intervention for amyotrophic lateral sclerosis (ALS): understanding the molecular mechanisms of action -- Chapter 7. Role of cannabinoids in the regulation of amyotrophic lateral sclerosis (ALS) -- Chapter 8. Neurobiology of cannabinoids and medical cannabis in therapeutic intervention for multiple sclerosis: understanding the molecular mechanisms of action -- Chapter 9. Pros and cons of cannabinoids as a potential therapeutic target for treating Parkinson's disease: cannabinoid receptor-mediated mechanism of action -- Chapter 10. The uses of cannabinoids in medicine and their spectroscopic applications -- Chapter 11. Therapeutic advantages of cannabimimetic plants: can they substitute medical cannabis? -- Chapter 12. History and legislative changes governing medical cannabis in Indonesia -- Chapter 13. A case study on the integration of cannabis law enforcement in new jersey. |
| ctrlnum | (CaBNVSL)slc00004108 (OCoLC)1348644527 |
| dewey-full | 615.3/23648 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.3/23648 |
| dewey-search | 615.3/23648 |
| dewey-sort | 3615.3 523648 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06899nam a2200613 i 4500</leader><controlfield tag="001">ZDB-98-IGB-00296569</controlfield><controlfield tag="003">IGIG</controlfield><controlfield tag="005">20230313190106.0</controlfield><controlfield tag="006">m eo d </controlfield><controlfield tag="007">cr bn||||m|||a</controlfield><controlfield tag="008">230310s2023 pau fob 001 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781668456538</subfield><subfield code="q">PDF</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1668456524</subfield><subfield code="q">hardcover</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781668456521</subfield><subfield code="q">print</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4018/978-1-6684-5652-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CaBNVSL)slc00004108</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1348644527</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">CaBNVSL</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">CaBNVSL</subfield><subfield code="d">CaBNVSL</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM666.C266</subfield><subfield code="b">M43 2023e</subfield></datafield><datafield tag="060" ind1="0" ind2="0"><subfield code="a">WB 925</subfield><subfield code="b">.M43 2023e</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.3/23648</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases </subfield><subfield code="c">Rana R. Zeine and Brian W. Teasdale.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hershey, Pennsylvania (701 E. Chocolate Avenue, Hershey, Pennsylvania, 17033, USA) </subfield><subfield code="b">IGI Global</subfield><subfield code="c">2023.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">20 PDFs (406 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">electronic</subfield><subfield code="2">isbdmedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Chapter 1. Medicinal cannabis for Alzheimer's disease -- Chapter 2. Protective effects of cannabis in neuroinflammation-mediated Alzheimer's disease -- Chapter 3. Cannabinoid efficacy for developmental epileptic encephalopathy (DEE) intractable seizure control: a systematic review of the literature -- Chapter 4. Medical cannabis in the treatment of epilepsy -- Chapter 5. Anti-tumor effects of cannabinoids in brain, lung, breast, prostate, colorectal, and pancreatic cancers: a systematic review of the literature -- Chapter 6. Cannabinoid neurobiology and medical cannabis intervention for amyotrophic lateral sclerosis (ALS): understanding the molecular mechanisms of action -- Chapter 7. Role of cannabinoids in the regulation of amyotrophic lateral sclerosis (ALS) -- Chapter 8. Neurobiology of cannabinoids and medical cannabis in therapeutic intervention for multiple sclerosis: understanding the molecular mechanisms of action -- Chapter 9. Pros and cons of cannabinoids as a potential therapeutic target for treating Parkinson's disease: cannabinoid receptor-mediated mechanism of action -- Chapter 10. The uses of cannabinoids in medicine and their spectroscopic applications -- Chapter 11. Therapeutic advantages of cannabimimetic plants: can they substitute medical cannabis? -- Chapter 12. History and legislative changes governing medical cannabis in Indonesia -- Chapter 13. A case study on the integration of cannabis law enforcement in new jersey.</subfield></datafield><datafield tag="506" ind1=" " ind2=" "><subfield code="a">Restricted to subscribers or individual electronic text purchasers.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">"Research into the efficacy of medical marijuana is currently at different stages for different types of diseases. The most advanced studies in humans provide moderate-quality evidence for moderate effects that benefit patients with Parkinson Disease and Multiple Sclerosis. There is also low-quality evidence for mild-to-moderate effects that benefit patients with Epilepsy and Huntington Disease. The best success in reducing spasticity, relieving pain, decreasing bladder overactivity, reducing anxiety and improving quality of sleep was achieved using a 50:50 mixture of Cannabidiol (CBD):delta-9-THC. Reducing frequency and duration of seizures in children with intractable epilepsy is achieved using CBD alone. Future studies can hopefully improve the quality of evidence by including control groups, recruiting more participants, and following them up for longer periods of time. In the meanwhile, the cellular and molecular mechanisms responsible for alleviating these neurological symptoms in animals and humans are being investigated. Some of the anti-inflammatory and neuroprotective effects are mediated through one or both of the cannabinoid receptors CB1 and CB2 distributed on immune and neural cells, while some of the anti-epileptic effects are mediated through other receptors found in the central nervous system. Animal studies show that cannabinoids are effective anti-inflammatory and anti-tumor agents. In experimental xenograft models for brain cancer, lung, breast, colorectal, pancreatic and other cancers, treatment with either CBD alone or in mixtures with THC, significantly shrinks the tumors, inhibits tumor cell migration, slows metastasis, disrupts tumor blood vessel formation (angiogenesis), inhibits tumor cell proliferation and increases tumor cell death. Future studies are warranted to investigate these anti-tumor effects in human cancer patients, however, a small study on a dozen brain cancer patients demonstrated a modest increase in overall survival, and a case study on a lung cancer patient who refused chemotherapy and used cannabinoids instead reported a remarkable regression of the lung cancer tumors. Research efforts are intensifying to elucidate the multitude of cell signaling mechanisms that might be involved in mediating these remarkable anti-cancer and anti-angiogenic effects. The implications are that the next decade will be the dawn of a new era of pharmacotherapeutic applications of medical marijuana treatments in oncology for all cancer types, neurology for all movement disorders, demyelinative and dementia-causing neurodegenerative diseases, rheumatology and gastroenterology for all autoimmune and inflammatory disorders, and palliative care medicine for anxiety and pain management. This publication will include 15 chapters by experts on the use of cannabinoids and medical marijuana in different types of cancer and different types of neurologic or inflammatory diseases. Some authors will discuss the physiologic and biochemical mechanisms while others will report on clinical benefits and pharmacological challenges"--</subfield><subfield code="c">Provided by publisher.</subfield></datafield><datafield tag="530" ind1=" " ind2=" "><subfield code="a">Also available in print.</subfield></datafield><datafield tag="538" ind1=" " ind2=" "><subfield code="a">Mode of access: World Wide Web.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on title screen (IGI Global, viewed 03/10/2023).</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Marijuana</subfield><subfield code="x">Therapeutic use.</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Cannabinoids</subfield><subfield code="x">analysis.</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Medical Marijuana</subfield><subfield code="x">therapeutic use.</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Neurodegenerative Diseases</subfield><subfield code="x">drug therapy.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Cancer.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Developmental Epileptic Encephalopathies (DEE)</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Epilepsy.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Ethical Issues.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Medical Marijuana.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Multiple Sclerosis.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Neurobiology of Cannabinoids.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Neurodegenerative Diseases.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Parkinson's.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Spectroscopic Applications.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Therapeutic Intervention.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Teasdale, Brian</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zeine, Rana</subfield><subfield code="d">1962-</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">IGI Global,</subfield><subfield code="e">publisher.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="z">1668456524</subfield><subfield code="z">9781668456521</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-863</subfield><subfield code="p">ZDB-98-IGB</subfield><subfield code="q">FWS_PDA_IGB</subfield><subfield code="u">http://services.igi-global.com/resolvedoi/resolve.aspx?doi=10.4018/978-1-6684-5652-1</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-98-IGB</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-98-IGB-00296569 |
| illustrated | Not Illustrated |
| indexdate | 2025-03-07T12:04:10Z |
| institution | BVB |
| isbn | 9781668456538 |
| language | English |
| oclc_num | 1348644527 |
| open_access_boolean | |
| owner | DE-863 DE-BY-FWS |
| owner_facet | DE-863 DE-BY-FWS |
| physical | 20 PDFs (406 Seiten) Also available in print. |
| psigel | ZDB-98-IGB FWS_PDA_IGB ZDB-98-IGB |
| publishDate | 2023 |
| publishDateSearch | 2023 |
| publishDateSort | 2023 |
| publisher | IGI Global |
| record_format | marc |
| spelling | Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases Rana R. Zeine and Brian W. Teasdale. Hershey, Pennsylvania (701 E. Chocolate Avenue, Hershey, Pennsylvania, 17033, USA) IGI Global 2023. 20 PDFs (406 Seiten) text rdacontent electronic isbdmedia online resource rdacarrier Includes bibliographical references and index. Chapter 1. Medicinal cannabis for Alzheimer's disease -- Chapter 2. Protective effects of cannabis in neuroinflammation-mediated Alzheimer's disease -- Chapter 3. Cannabinoid efficacy for developmental epileptic encephalopathy (DEE) intractable seizure control: a systematic review of the literature -- Chapter 4. Medical cannabis in the treatment of epilepsy -- Chapter 5. Anti-tumor effects of cannabinoids in brain, lung, breast, prostate, colorectal, and pancreatic cancers: a systematic review of the literature -- Chapter 6. Cannabinoid neurobiology and medical cannabis intervention for amyotrophic lateral sclerosis (ALS): understanding the molecular mechanisms of action -- Chapter 7. Role of cannabinoids in the regulation of amyotrophic lateral sclerosis (ALS) -- Chapter 8. Neurobiology of cannabinoids and medical cannabis in therapeutic intervention for multiple sclerosis: understanding the molecular mechanisms of action -- Chapter 9. Pros and cons of cannabinoids as a potential therapeutic target for treating Parkinson's disease: cannabinoid receptor-mediated mechanism of action -- Chapter 10. The uses of cannabinoids in medicine and their spectroscopic applications -- Chapter 11. Therapeutic advantages of cannabimimetic plants: can they substitute medical cannabis? -- Chapter 12. History and legislative changes governing medical cannabis in Indonesia -- Chapter 13. A case study on the integration of cannabis law enforcement in new jersey. Restricted to subscribers or individual electronic text purchasers. "Research into the efficacy of medical marijuana is currently at different stages for different types of diseases. The most advanced studies in humans provide moderate-quality evidence for moderate effects that benefit patients with Parkinson Disease and Multiple Sclerosis. There is also low-quality evidence for mild-to-moderate effects that benefit patients with Epilepsy and Huntington Disease. The best success in reducing spasticity, relieving pain, decreasing bladder overactivity, reducing anxiety and improving quality of sleep was achieved using a 50:50 mixture of Cannabidiol (CBD):delta-9-THC. Reducing frequency and duration of seizures in children with intractable epilepsy is achieved using CBD alone. Future studies can hopefully improve the quality of evidence by including control groups, recruiting more participants, and following them up for longer periods of time. In the meanwhile, the cellular and molecular mechanisms responsible for alleviating these neurological symptoms in animals and humans are being investigated. Some of the anti-inflammatory and neuroprotective effects are mediated through one or both of the cannabinoid receptors CB1 and CB2 distributed on immune and neural cells, while some of the anti-epileptic effects are mediated through other receptors found in the central nervous system. Animal studies show that cannabinoids are effective anti-inflammatory and anti-tumor agents. In experimental xenograft models for brain cancer, lung, breast, colorectal, pancreatic and other cancers, treatment with either CBD alone or in mixtures with THC, significantly shrinks the tumors, inhibits tumor cell migration, slows metastasis, disrupts tumor blood vessel formation (angiogenesis), inhibits tumor cell proliferation and increases tumor cell death. Future studies are warranted to investigate these anti-tumor effects in human cancer patients, however, a small study on a dozen brain cancer patients demonstrated a modest increase in overall survival, and a case study on a lung cancer patient who refused chemotherapy and used cannabinoids instead reported a remarkable regression of the lung cancer tumors. Research efforts are intensifying to elucidate the multitude of cell signaling mechanisms that might be involved in mediating these remarkable anti-cancer and anti-angiogenic effects. The implications are that the next decade will be the dawn of a new era of pharmacotherapeutic applications of medical marijuana treatments in oncology for all cancer types, neurology for all movement disorders, demyelinative and dementia-causing neurodegenerative diseases, rheumatology and gastroenterology for all autoimmune and inflammatory disorders, and palliative care medicine for anxiety and pain management. This publication will include 15 chapters by experts on the use of cannabinoids and medical marijuana in different types of cancer and different types of neurologic or inflammatory diseases. Some authors will discuss the physiologic and biochemical mechanisms while others will report on clinical benefits and pharmacological challenges"-- Provided by publisher. Also available in print. Mode of access: World Wide Web. Description based on title screen (IGI Global, viewed 03/10/2023). Marijuana Therapeutic use. Cannabinoids analysis. Medical Marijuana therapeutic use. Neurodegenerative Diseases drug therapy. Cancer. Developmental Epileptic Encephalopathies (DEE) Epilepsy. Ethical Issues. Medical Marijuana. Multiple Sclerosis. Neurobiology of Cannabinoids. Neurodegenerative Diseases. Parkinson's. Spectroscopic Applications. Therapeutic Intervention. Teasdale, Brian editor. Zeine, Rana 1962- editor. IGI Global, publisher. Print version: 1668456524 9781668456521 |
| spellingShingle | Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases Chapter 1. Medicinal cannabis for Alzheimer's disease -- Chapter 2. Protective effects of cannabis in neuroinflammation-mediated Alzheimer's disease -- Chapter 3. Cannabinoid efficacy for developmental epileptic encephalopathy (DEE) intractable seizure control: a systematic review of the literature -- Chapter 4. Medical cannabis in the treatment of epilepsy -- Chapter 5. Anti-tumor effects of cannabinoids in brain, lung, breast, prostate, colorectal, and pancreatic cancers: a systematic review of the literature -- Chapter 6. Cannabinoid neurobiology and medical cannabis intervention for amyotrophic lateral sclerosis (ALS): understanding the molecular mechanisms of action -- Chapter 7. Role of cannabinoids in the regulation of amyotrophic lateral sclerosis (ALS) -- Chapter 8. Neurobiology of cannabinoids and medical cannabis in therapeutic intervention for multiple sclerosis: understanding the molecular mechanisms of action -- Chapter 9. Pros and cons of cannabinoids as a potential therapeutic target for treating Parkinson's disease: cannabinoid receptor-mediated mechanism of action -- Chapter 10. The uses of cannabinoids in medicine and their spectroscopic applications -- Chapter 11. Therapeutic advantages of cannabimimetic plants: can they substitute medical cannabis? -- Chapter 12. History and legislative changes governing medical cannabis in Indonesia -- Chapter 13. A case study on the integration of cannabis law enforcement in new jersey. Marijuana Therapeutic use. Cannabinoids analysis. Medical Marijuana therapeutic use. Neurodegenerative Diseases drug therapy. |
| title | Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases |
| title_auth | Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases |
| title_exact_search | Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases |
| title_full | Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases Rana R. Zeine and Brian W. Teasdale. |
| title_fullStr | Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases Rana R. Zeine and Brian W. Teasdale. |
| title_full_unstemmed | Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases Rana R. Zeine and Brian W. Teasdale. |
| title_short | Medical cannabis and the effects of cannabinoids on fighting cancer, multiple sclerosis, epilepsy, Parkinson's, and other neurodegenerative diseases |
| title_sort | medical cannabis and the effects of cannabinoids on fighting cancer multiple sclerosis epilepsy parkinson s and other neurodegenerative diseases |
| topic | Marijuana Therapeutic use. Cannabinoids analysis. Medical Marijuana therapeutic use. Neurodegenerative Diseases drug therapy. |
| topic_facet | Marijuana Therapeutic use. Cannabinoids analysis. Medical Marijuana therapeutic use. Neurodegenerative Diseases drug therapy. |
| work_keys_str_mv | AT teasdalebrian medicalcannabisandtheeffectsofcannabinoidsonfightingcancermultiplesclerosisepilepsyparkinsonsandotherneurodegenerativediseases AT zeinerana medicalcannabisandtheeffectsofcannabinoidsonfightingcancermultiplesclerosisepilepsyparkinsonsandotherneurodegenerativediseases AT igiglobal medicalcannabisandtheeffectsofcannabinoidsonfightingcancermultiplesclerosisepilepsyparkinsonsandotherneurodegenerativediseases |